




DOCKET NO.: C1039.70077US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.  
Serial No.: 10/619,279  
Confirmation No.: 8248  
Filed: July 14, 2003  
For: IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES  
Examiner: Janet L. Epps Ford  
Art Unit: 1633

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 6<sup>th</sup> day of October, 2006.

  
Emily E. Zukauskas

MAIL STOP AMENDMENT

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:


- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check in the amount of \$180 is enclosed to cover the filing fee. If the fee is insufficient, the balance may be charged to Deposit Account 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:

  
Helen C. Lockhart, Ph.D., Reg. No.: 39,248  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: C1039.70077US00  
Date: October 6, 2006  
xNDDx



DOCKET NO.: C1039.70077US00


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.  
Serial No.: 10/619,279  
Confirmation No.: 8248  
Filed: July 14, 2003  
For: IMMUNOSTIMULATORY NUCLEIC ACID  
MOLECULES  
Examiner: Janet L. Epps Ford  
Art Unit: 1633

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 6<sup>th</sup> day of October, 2006.

  
Emily E. Zukauskas

---

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

**PART I: Compliance with 37 C.F.R. §1.97**

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Docket No.</u>
10/532,746	04-26-2005	Ahluwalia et al.	*C1037.70035US01
10/811,226	03-26-2004	Wagner et al.	*C1041.70005US01
11/179,008	07-08-2005	Hartmann et al.	*C1039.70044US02
11/301,360	12-09-2005	Bratzler et al.	*C1037.70013US02
11/361,313	02-24-2006	Krieg et al.	*C1037.70060US01
11/368,333	03-03-2006	Lipford et al.	*C1041.70037US01
11/368,334	03-03-2006	Krieg et al.	*C1039.70065US01
11/401,093	04-10-2006	Krieg et al.	*C1037.70062US01
11/411,975	04-26-2006	Uhlmann et al.	*C1041.70045US01

\*A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:



Helen C. Lockhart, Ph.D., Reg. No. 39,248  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: C1039.70077US00  
Date: October 6, 2006  
**xNDDx**

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

APPLICATION NO.: 10/619,279

ATTY. DOCKET NO.: C1039.70077US00

FILING DATE: July 14, 2003

CONFIRMATION NO.: 8248

APPLICANT: Krieg et al.

GROUP ART UNIT: 1633

EXAMINER: Janet L. Epps Ford

Sheet

1

of

13

OCT 10 2006

## **U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,087,617		Smith	02-11-1992
		5,457,189		Crooke et al.	10-10-1995
		5,475,096		Gold et al.	12-12-1995
		5,514,577		Draper et al.	05-07-1996
		5,576,208		Monia et al.	11-19-1996
		5,576,302		Cook et al.	11-19-1996
		5,582,986		Monia et al.	12-10-1996
		5,670,637		Gold et al.	09-23-1997
		5,679,647		Carson et al.	10-21-1997
		5,684,147		Agrawal et al.	11-04-1997
		5,696,249		Gold et al.	12-09-1997
		5,804,566		Carson et al.	09-08-1998
		5,849,719		Carson et al.	12-15-1998
		5,955,059		Gilchrest et al.	09-21-1999
		5,977,340		Pirotzky et al.	11-02-1999
		5,994,315		Nyce et al.	11-30-1999
		6,025,339		Nyce et al.	02-15-2000
		6,030,955		Stein et al.	02-29-2000
		6,040,296		Nyce et al.	03-21-2000
		6,174,872	B1	Carson et al.	01-16-2001
		6,194,388	B1	Krieg et al.	02-27-2001
		6,207,646	B1	Krieg et al.	03-27-2001
		6,214,806	B1	Krieg et al.	04-10-2001
		6,218,371	B1	Krieg et al.	04-17-2001
		6,221,882		Macfarlane	04-24-2001
		6,225,292	B1	Raz et al.	05-01-2001
		6,239,116	B1	Krieg et al.	05-29-2001
		6,339,068	B1	Krieg et al.	01-15-2002
		6,339,630		Macfarlane	06-04-2002
		6,406,705	B1	Davis et al.	06-18-2002
		6,426,336	B1	Carson et al.	07-30-2002
		6,429,199	B1	Krieg et al.	08-06-2002

EXAMINER:

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
				FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Janet L. Epps Ford
Sheet	2	of	13		

	6,479,504		Macfarlane et al.	11-12-2002
	6,498,147	B1	Nerenberg et al.	12-24-2002
	6,498,148	B1	Raz	12-24-2002
	6,503,533	B1	Korba et al.	01-07-2003
	6,521,637		Macfarlane	02-18-2003
	6,558,670	B1	Friede et al.	05-06-2003
	6,589,940	B1	Raz et al.	07-08-2003
	6,562,798	B1	Schwartz	05-13-2003
	6,610,308		Haensler	08-26-2003
	6,610,661	B1	Carson et al.	08-26-2003
	6,727,230	B1	Hutcherson et al.	04-27-2004
	6,737,066	B1	Moss	05-18-2004
	6,821,957	B1	Krieg et al.	11-23-2004
	6,835,395	B1	Semple et al.	12-28-2004
	6,943,240		Bauer et al.	09-13-2005
	6,949,520		Hartmann et al.	09-27-2005
	7,001,890		Wagner et al.	02-26-2006
	2001-0021772	A1	Uhlmann et al.	09-13-2001
	2002-0086839	A1	Raz et al.	07-04-2002
	2002-0091097	A1	Bratzler et al.	07-11-2002
	2002-0164341	A1	Davis et al.	11-07-2002
	2003-0026801	A1	Weiner et al.	02-06-2003
	2003-0027782	A1	Carson et al.	02-06-2003
	2003-0050261	A1	Krieg et al.	03-13-2003
	2003-0050268	A1	Krieg et al.	03-13-2003
	2003-0060440	A1	Klinman et al.	03-27-2003
	2003-0064064	A1	Dina et al.	04-03-2003
	2003-0078223	A1	Raz et al.	04-24-2003
	2003-0091599	A1	Davis et al.	05-15-2003
	2003-0092663	A1	Raz et al.	05-15-2003
	2003-0100527	A1	Krieg et al.	05-29-2003
	2003-0109469	A1	Carson et al.	06-12-2003
	2003-0139364	A1	Krieg et al.	07-24-2003
	2003-0148316	A1	Lipford et al.	08-07-2003
	2003-0148976	A1	Krieg et al.	08-07-2003

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279		ATTY. DOCKET NO.: C1039.70077US00			
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 8248			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1633		EXAMINER: Janet L. Epps Ford			
Sheet	3	of	13						

		2003-0181406	A1	Schetter et al.	09-25-2003
		2003-0186921	A1	Carson et al.	10-02-2003
		2003-0191079	A1	Krieg et al.	10-09-2003
		2003-0203861	A1	Carson et al.	10-30-2003
		2003-0212026	A1	Krieg et al.	11-13-2003
		2003-0224010	A1	Davis et al.	12-04-2003
		2003-0232074	A1	Lipford et al.	12-18-2003
		2003-0232780	A1	Carson et al.	12-18-2003
		2003-0232856	A1	Macfarlane	12-18-2003
		2004-0006010	A1	Carson et al.	01-08-2004
		2004-0006034	A1	Raz et al.	01-08-2004
		2004-0009942	A1	Van Nest et al.	01-15-2004
		2004-0009949	A1	Krieg	01-15-2004
		2004-0030118	A1	Wagner et al.	02-12-2004
		2004-0053880	A1	Krieg	03-18-2004
		2004-0067902	A9	Bratzler et al.	04-08-2004
		2004-0067905	A1	Krieg	04-08-2004
		2004-0087534	A1	Krieg et al.	05-06-2004
		2004-0087538	A1	Krieg et al.	05-06-2004
		2004-0092468	A1	Schwartz et al.	05-13-2004
		2004-0092472	A1	Krieg	05-13-2004
		2004-0105872	A1	Klinman et al.	06-03-2004
		2004-0106568	A1	Krieg et al.	06-03-2004
		2004-0131628	A1	Bratzler et al.	07-08-2004
		2004-0132685	A1	Krieg et al.	07-08-2004
		2004-0142469	A1	Krieg et al.	07-22-2004
		2004-0143112	A1	Krieg et al.	07-22-2004
		2004-0147468	A1	Krieg et al.	07-29-2004
		2004-0152649	A1	Krieg	08-05-2004
		2004-0152656	A1	Krieg et al.	08-05-2004
		2004-0152657	A1	Krieg et al.	08-05-2004
		2004-0162258	A1	Krieg et al.	08-19-2004
		2004-0162262	A1	Krieg et al.	08-19-2004
		2004-0167089	A1	Krieg et al.	08-26-2004
		2004-0171150	A1	Krieg et al.	09-02-2004

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279		ATTY. DOCKET NO.: C1039.70077US00			
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 8248			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1633		EXAMINER: Janet L. Epps Ford			
Sheet	4	of	13						

		2004-0171571	A1	Krieg et al.	09-02-2004
		2004-0181045	A1	Krieg et al.	09-16-2004
		2004-0198680	A1	Krieg	10-07-2004
		2004-0198688	A1	Krieg et al.	10-07-2004
		2004-0229835	A1	Krieg et al.	11-18-2004
		2004-0234512	A1	Wagner et al.	11-25-2004
		2004-0235770	A1	Davis et al.	11-25-2004
		2004-0235774	A1	Bratzler et al.	11-25-2004
		2004-0235777	A1	Wagner et al.	11-25-2004
		2004-0235778	A1	Wagner et al.	11-25-2004
		2004-0247662	A1	Dow et al.	12-09-2004
		2004-0266719	A1	McCluskie et al.	12-30-2004
		2005-0004061	A1	Krieg et al.	01-06-2005
		2005-0004062	A1	Krieg et al.	01-06-2005
		2005-0009774	A1	Krieg et al.	01-13-2005
		2005-0013812	A1	Dow et al.	01-20-2005
		2005-0032734	A1	Davis et al.	02-10-2005
		2005-0032736	A1	Krieg et al.	02-10-2005
		2005-0037403	A1	Krieg et al.	02-17-2005
		2005-0037985	A1	Krieg et al.	02-17-2005
		2005-0043529	A1	Davis et al.	02-24-2005
		2005-0049215	A1	Krieg et al.	03-03-2005
		2005-0049216	A1	Krieg et al.	03-03-2005
		2005-0054601	A1	Wagner et al.	03-10-2005
		2005-0054602	A1	Krieg et al.	03-10-2005
		2005-0059619	A1	Krieg et al.	03-17-2005
		2005-0059625	A1	Krieg et al.	03-17-2005
		2005-0059626	A1	Van Nest et al.	03-17-2005
		2005-0070491	A1	Krieg et al.	03-31-2005
		2005-0075302	A1	Hutcherson et al.	04-07-2005
		2005-0100983	A1	Bauer et al.	05-12-2005
		2005-0101554	A1	Krieg et al.	05-12-2005
		2005-0101557	A1	Krieg et al.	05-12-2005
		2005-0119273	A1	Lipford et al.	06-02-2005
		2005-0123523	A1	Krieg et al.	06-09-2005

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
				FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Janet L. Epps Ford
Sheet	5	of	13		

		2005-0130911	A1	Uhlmann et al.	06-16-2005
		2005-0148537	A1	Krieg et al.	07-07-2005
		2005-0169888	A1	Hartman et al.	08-04-2005
		2005-0171047	A1	Krieg et al.	08-04-2005
		2005-0181422	A1	Bauer et al.	08-18-2005
		2005-0182017	A1	Krieg	08-18-2005
		2005-0197314	A1	Krieg et al.	09-08-2005
		2005-0215500	A1	Krieg et al.	09-29-2005
		2005-0215501	A1	Lipford et al.	09-29-2005
		2005-0233995	A1	Krieg et al.	10-20-2005
		2005-0233999	A1	Krieg et al.	10-20-2005
		2005-0239732	A1	Krieg et al.	10-27-2005
		2005-0239733	A1	Jurk et al.	10-27-2005
		2005-0239734	A1	Uhlmann et al.	10-27-2005
		2005-0239736	A1	Krieg et al.	10-27-2005
		2005-0245477	A1	Krieg et al.	11-03-2005
		2005-0244379	A1	Krieg et al.	11-03-2005
		2005-0244380	A1	Krieg et al.	11-03-2005
		2005-0250726	A1	Krieg et al.	11-10-2005
		2005-0256073	A1	Lipford et al.	11-17-2005
		2005-0267057	A1	Krieg	12-01-2005
		2005-0267064	A1	Krieg et al.	12-01-2005
		2005-0277604	A1	Krieg et al.	12-15-2005
		2005-0277609	A1	Krieg et al.	12-15-2005
		2006-0003955	A1	Krieg et al.	01-05-2006
		2006-0003962	A1	Ahluwalia et al.	01-05-2006
		2006-0019916	A1	Krieg et al.	01-26-2006
		2006-0019923	A1	Davis et al.	01-26-2006
		2006-0058251	A1	Krieg et al.	03-16-2006
		2006-0089326	A1	Krieg et al.	04-27-2006
		2006-0094683	A1	Krieg et al.	05-04-2006
		2006-0140875		Krieg et al.	06-29-2006

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279		ATTY. DOCKET NO.: C1039.70077US00			
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 8248			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1633		EXAMINER: Janet L. Epps Ford			
Sheet	6	of	13						

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		WO	96/40162	A1	East Carolina University	12-19-1996	
		WO	98/52962	A1	Merck and Co., Inc.	11-26-1998	
		WO	99/33488	A2	SmithKline Beecham Biologicals S.A.	07-08-1999	
		WO	99/52549	A1	SmithKline Beecham Biologicals S.A.	10-29-1999	
		WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
		WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000	
		WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Y-Abstract
		WO	00/20039	A1	The Regents of the University of California	04-13-2000	
		WO	00/21556	A1	Dynavax Technologies Corporation	04-20-2000	
		WO	00/61151	A2	The Government of the United States of America	10-19-2000	
		WO	2004/007743	A2	Coley Pharmaceutical GmbH	01-22-2004	
		WO	2004/026888	A2	Coley Pharmaceutical GmbH	04-01-2004	
		WO	2004/094671	A2	Coley Pharmaceutical GmbH	11-04-2004	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] Antiviral Agents Bulletin. 5(6), 1992.	
		[No Author Listed] New England BIOLABS Catalog. 1993-1994.	
		[No Author Listed] Promega Catalog. 1993-1994.	
		AGRAWAL et al., In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):245-9.	
		AGRAWAL et al., Antisense therapeutics: is it as simple as complementary base recognition? Mol Med Today. 2000 Feb;6(2):72-81.	
		AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar;8(3):114-21.	
		AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. p525-43.	
		AGRAWAL et al., Antisense oligonucleotides: towards clinical trials. Trends in Biotechnology, 1996; 14: 376-87.	
		AMMERPOHL et al., Complex protein binding to the mouse M-lysozyme gene downstream enhancer involves single-stranded DNA binding. Gene. 1997 Oct 24;200(1-2):75-84.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
				FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Janet L. Epps Ford
Sheet	7	of	13		

		AN et al., Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry. 1994 Dec 6;33(48):14496-502.	
		ANDERSON et al., Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996 Jun 1;97(11):2672-9.	
		ANDERSON et al., TH2 and 'TH2-like' cells in allergy and asthma: pharmacological perspectives. Trends Pharmacol Sci. 1994 Sep;15(9):324-32.	
		ASADULLAH et al., IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest. 1998 Feb 15;101(4):783-94.	
		BENIMETSKAYA et al., Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide. Nucleic Acids Res. 1997 Jul 1;25(13):2648-56.	
		BISHOP et al., Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J Biol Chem. 1996 Mar 8;271(10):5698-703.	
		BURGESS et al., The antiproliferative activity of c-myc and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4051-5.	
		CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.	
		CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
		COHEN, Selective anti-gene therapy for cancer: principles and prospects. Tohoku J Exp Med. 1992 Oct;168(2):351-9.	
		CONSTANT et al., Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol. 1997;15:297-322.	
		CONSTANT et al., Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science. 1994 Apr 8;264(5156):267-70.	
		COSSUM et al., Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993 Dec;267(3):1181-90.	
		COWSERT et al., In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993 Feb;37(2):171-7.	
		CROOKE et al., Phosphorothioate Oligonucleotides. Therapeut Apps. 1995;ch5:63-84.	
		CROOKE et al., Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:107-29.	
		DURHAM et al., Immunotherapy and allergic inflammation. Clin Exp Allergy. 1991 Jan;21 Suppl 1:206-10.	
		FULTZ et al., Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. AIDS Res Hum Retroviruses. 1992 Feb;8(2):313-7.	
		GALLICHAN et al., Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine. 1995 Nov;13(16):1589-95.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
				FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Janet L. Epps Ford
Sheet	8	of	13		

	GASTON et al., CpG methylation has differential effects on the binding of YY1 and ETS proteins to the bi-directional promoter of the Surf-1 and Surf-2 genes. <i>Nucleic Acids Res.</i> 1995 Mar 25;23(6):901-9.	
	GEISSLER et al., Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. <i>J Immunol.</i> 1997 Feb 1;158(3):1231-7.	
	GEWIRTZ et al., G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myc. <i>Science.</i> 1989 Jul 14;245(4914):180-3.	
	HAHM et al., Efficacy of polyadenylic-polyuridylic acid in the treatment of chronic active hepatitis B. <i>Int J Immunopharmacol.</i> 1994 Mar;16(3):217-25.	
	HARRINGTON et al., Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine. <i>Infect Immun.</i> 1979 Apr;24(1):160-6.	
	HARTMANN et al., Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. <i>J Immunol.</i> 2000 Feb 1;164(3):1617-24.	
	HARTMANN et al., Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1996 Winter;6(4):291-9.	
	HIGAKI et al., Mechanisms involved in the inhibition of growth of a human B lymphoma cell line, B104, by anti-MHC class II antibodies. <i>Immunol Cell Biol.</i> 1994 Jun;72(3):205-14.	
	HINKULA et al., Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. <i>J Virol.</i> 1997 Jul;71(7):5528-39.	
	HOGG et al., The pathology of asthma. <i>APMIS.</i> 1997 Oct;105(10):735-45.	
	HUGHES et al., Influence of base composition on membrane binding and cellular uptake of 10-mer phosphorothioate oligonucleotides in Chinese hamster ovary (CHRC5) cells. <i>Antisense Res Dev.</i> 1994 Fall;4(3):211-5.	
	ISHIKAWA et al., IFN induction and associated changes in splenic leukocyte distribution. <i>J Immunol.</i> 1993 May 1;150(9):3713-27.	
	JOHNSON et al., Immunopharmacology, Infection, and Disease, 291-301, 1987.	
	KERN et al., Herpesvirus hominis infection in newborn mice: treatment with interferon inducer polyinosinic-polycytidylic acid. <i>Antimicrob Agents Chemother.</i> 1975 Jun;7(6):793-800.	
	KITAGAKI et al., Microbial DNA and Host Immunity. Chapter 24. page 301.	
	KLINMAN et al., Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. <i>J Immunol.</i> 1998 Mar 15;160(6):2555-9.	
	KLINMAN et al., CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. <i>J Allergy Clin Immunol.</i> 1999 Dec;104(6):1258-64.	
	KLINMAN et al., Immunotherapeutic uses of CpG oligodeoxynucleotides. <i>Nature Reviews.</i> 2004 Apr;4:1-10.	
	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. <i>Drug News Perspect.</i> 2000 Jun;13(5):289-96.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
				FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Janet L. Epps Ford
Sheet	9	of	13		

	KLINMAN et al., Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun. 1999 Nov;67(11):5658-63.	
	KLINMAN et al., Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Springer Semin Immunopathol. 2000;22(1-2):173-83.	
	KLINMAN et al., Immune recognition of foreign DNA: a cure for bioterrorism? Immunity. 1999 Aug;11(2):123-9.	
	KOU et al., [Analysis and regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma] Arerugi. 1994 Mar;43(3):482-91. Abstract Only.	
	KRIEG et al., Immune effects and therapeutic applications of CpG motifs in bacterial DNA. Immunopharmacology. 2000 Jul 25;48(3):303-5.	
	KRIEG et al., American College of Rheumatology 58 <sup>th</sup> National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
	KRIEG et al., Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy. Eur J Canc. 1999 Oct; 35/Suppl4:S10. Abstract #14.	
	KRIEG et al., CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-60.	
	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct;21(10):521-6.	
	KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. in Antisense Research and Application. Crooke, editor. 1998; 243-62.	
	KRIEG et al., 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996: p116.	
	KRIEG et al., Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 Feb;3(1):15-24.	
	KRIEG et al., Chapter 7: CpG oligonucleotides as immune adjuvants. Ernst Schering Research Found Workshop 2001; 30:105-18.	
	KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000 Nov 8;19(6):618-22.	
	KRIEG et al., Chapter 17: Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	
	KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
	KRIEG, The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb;12(1):35-43.	
	KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
	KRIEG et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. 1999 Nov;84(2):113-20.	
	KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
				FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Janet L. Epps Ford
Sheet	10	of	13		

	KRIEG et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 1;161(5):2428-34.	
	KRIEG et al., CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb;7(2):64-5.	
	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.	
	KRIEG et al., How to exclude immunostimulatory and other nonantisense effects of antisense oligonucleotides. Manual of Antisense. 1999:79-89.	
	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
	KRIEG et al., Infection. In McGraw Hill Book. 1996: 242-3.	
	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
	KROWN et al., Phase I trial with the interferon inducer polyI/poly-L-lysine (Poly ICL). Journal of Interferon Research, 3: 281-90, 1983.	
	KROWN et al., Interferons and interferon inducers in cancer treatment. Semin Oncol. 1986 Jun;13(2):207-17.	
	KULKARNI et al., Effect of dietary nucleotides on response to bacterial infections. JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):169-71.	
	KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.	
	LeCLERC et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol. 1997 Aug 1;179(2):97-106.	
	LEDERMAN et al., Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation. Antisense Nucleic Acid Drug Dev. 1996 Winter;6(4):281-9.	
	LEE et al., An oligonucleotide blocks interferon-gamma signal transduction. Transplantation. 1996 Nov 15;62(9):1297-301.	
	LETSINGER et al., Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6553-6.	
	LETSINGER et al., Synthesis and properties of modified oligonucleotides. Nucleic Acids Symp Ser. 1991;(24):75-8.	
	LEVINE et al., Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep. 1978 Nov;62(11):1907-12.	
	LEVY et al., Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer, polyribonucleosinic-polyribocytidylic acid-poly-L-lysine. J Infect Dis. 1976 Jun;133 Suppl:A256-9.	
	LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol. 1997 Dec;27(12):3420-6.	
	LIU et al., Recombinant interleukin-6 protects mice against experimental bacterial infection. Infect Immun. 1992 Oct;60(10):4402-6.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
				FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Janet L. Epps Ford
Sheet	11	of	13		

		LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. J Invest Med. 1997 Sept7;45(7):333A.	
		LOKE et al., Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis. Curr Top Microbiol Immunol. 1988;141:282-9.	
		LUKACS et al., Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J Respir Cell Mol Biol. 1994 May;10(5):526-32.	
		LUKACS et al., C-C chemokine-induced eosinophil chemotaxis during allergic airway inflammation. J Leukoc Biol. 1996 Nov;60(5):573-8.	
		MACAYA et al., Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3745-9.	
		MacFARLANE et al., Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step. Immunology. 1997 Aug;91(4):586-93.	
		MALTESE et al., Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity. Nucleic Acids Res. 1995 Apr 11;23(7):1146-51.	
		MANCILLA-RAMIREZ et al., [Phosphatidylcholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by Klebsiella pneumoniae] Gac Med Mex. 1995 Jan-Feb;131(1):14-22. Spanish. Abstract only.	Yes – Abstract
		MATSUKURA et al., Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4244-8.	
		MICHELSON et al. Poly(A).poly(U) as adjuvant in cancer treatment distribution and pharmacokinetics in rabbits. Proc Soc Exp Biol Med. 1985 Jun;179(2):180-6.	
		MONTEITH et al., Immune stimulation—a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des. 1997 Jul;12(5):421-32.	
		MOSMANN et al., The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996 Mar;17(3):138-46.	
		MUHLHAUSER et al., VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res. 1995 Dec;77(6):1077-86.	
		OCHIAI et al., Studies on lymphocyte subsets of regional lymph nodes after endoscopic injection of biological response modifiers in gastric cancer patients. Int J Immunotherapy. 1986;11(4):259-65.	
		PARK et al. Adjuvant effect of polyadenylic.polyuridylic acid on antibody production of recombinant hepatitis B surface antigen in mice. Int J Immunopharmacol. 1995 Jun;17(6):513-6.	
		PERLAKY et al., Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. Anticancer Drug Des. 1993 Feb;8(1):3-14.	
		PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63.	
		PISETSKY et al., Influence of backbone chemistry on immune activation by synthetic oligonucleotides. Biochem Pharmacol. 1999 Dec 15;58(12):1981-8.	
		PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. Immunol Res. 1999;19(1):35-46.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
				FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Janet L. Epps Ford
Sheet	12	of	13		

	RATAJCZAK et al., In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11823-7.	
	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract Number 615.	
	RICCI et al., T cells, cytokines, IgE and allergic airways inflammation. J Investig Allergol Clin Immunol. 1994 Sep-Oct;4(5):214-20.	
	ROBINSON et al., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992 Jan 30;326(5):298-304.	
	SATOH et al., Morphological and immunohistochemical characteristics of the heterogeneous prostate-like glands (paraurethral gland) seen in female Brown-Norway rats. Toxicol Pathol. 2001 Mar-Apr;29(2):237-41.	
	SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol. 1999 Jul 1;163(1):224-31.	
	SEDEGAH et al., Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10700-2.	
	SJOLANDER et al., Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. Scand J Immunol. 1996 Feb;43(2):164-72.	
	SJOLANDER et al., Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol. 1997 Apr 10;177(1):69-76.	
	SPARWASSER et al., Bacterial DNA causes septic shock. Nature. 1997 Mar 27;386(6623):336-7.	
	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	
	STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch11: 241-64.	
	STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12.	
	TAKATSUKI et al., Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment. Cancer Res. 1990 May 15;50(10):2885-90.	
	TALMADGE et al., Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. Cancer Res. 1985 Mar;45(3):1058-65.	
	TIGHE et al., Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol. 2000 Jul;30(7):1939-47.	
	TIGHE et al., Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):124-34.	
	VAN UDEN et al., Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol. 1999 Nov;104(5):902-10.	
	VERTHELYI et al., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol. 2003 Oct;109(1):64-71.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/619,279	ATTY. DOCKET NO.: C1039.70077US00
				FILING DATE: July 14, 2003	CONFIRMATION NO.: 8248
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1633	EXAMINER: Janet L. Epps Ford
Sheet	13	of	13		

		VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004 Jan;34(1):251-62.	
		WAAG et al., Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice. Ann N Y Acad Sci. 1990;590:203-14.	
		WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7.	
		WYATT et al. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1356-60.	
		ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.